{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:51:53Z","timestamp":1791553913918,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01712-7","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:21:39Z","timestamp":1791552099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Pharmacokinetic Modeling of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in Adults and Pediatric\u00a0People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9825-9357","authenticated-orcid":false,"given":"Clotilde","family":"Vellat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-0346","authenticated-orcid":false,"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-8335","authenticated-orcid":false,"given":"Philippe","family":"Reix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-4808","authenticated-orcid":false,"given":"Romain","family":"Garreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"1712_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519\u201331.","journal-title":"Lancet"},{"key":"1712_CR2","first-page":"564","volume":"114","author":"S Naehrig","year":"2017","unstructured":"Naehrig S, Chao C-M, Naehrlich L. Cystic fibrosis. Dtsch Arzteblatt Int. 2017;114:564\u201374.","journal-title":"Dtsch Arzteblatt Int."},{"key":"1712_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski JL, Hoppe JE, Mall MA, et al. Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2023;208:59\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"1712_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J, et al. A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203:1522\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"1712_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall MA, Brugha R, Gartner S, et al. Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study. Am J Respir Crit Care Med. 2022;206:1361\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1712_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809\u201319.","journal-title":"N Engl J Med"},{"key":"1712_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","volume":"404","author":"I Sermet-Gaudelus","year":"2024","unstructured":"Sermet-Gaudelus I, Benaboud S, Bui S, et al. Behavioural and sleep issues after initiation of elexacaftor\u2013tezacaftor\u2013ivacaftor in preschool-age children with cystic fibrosis. Lancet. 2024;404:117\u201320.","journal-title":"Lancet"},{"key":"1712_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","volume":"21","author":"G Spoletini","year":"2022","unstructured":"Spoletini G, Gillgrass L, Pollard K, et al. Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis. J Cyst Fibros. 2022;21:1061\u20135.","journal-title":"J Cyst Fibros"},{"key":"1712_CR9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/ppul.26412","volume":"58","author":"E Baroud","year":"2023","unstructured":"Baroud E, Chaudhary N, Georgiopoulos AM. Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor. Pediatr Pulmonol. 2023;58:1920\u201330.","journal-title":"Pediatr Pulmonol"},{"key":"1712_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","volume":"57","author":"Y Guo","year":"2009","unstructured":"Guo Y, Su M, McNutt MA, et al. Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain. J Histochem Cytochem. 2009;57:1113\u201320.","journal-title":"J Histochem Cytochem"},{"key":"1712_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.actpsy.2026.106210","volume":"263","author":"Q Ge","year":"2026","unstructured":"Ge Q, Fagan A, Lu H, et al. Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice. Acta Psychol (Amst). 2026;263:106210.","journal-title":"Acta Psychol (Amst)"},{"key":"1712_CR12","unstructured":"US FDA. Trikafta. Clinical pharmacology and biopharmaceutics reviews. AN: 203188Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf. Accessed 4 Apr 2024."},{"key":"1712_CR13","unstructured":"US FDA. Trikafta. Clinical pharmacology and biopharmaceutics reviews. AN: 210491Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000ClinPharmR.pdf. Accessed 25 Mar 2024."},{"key":"1712_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cts.12610","volume":"12","author":"V Garg","year":"2019","unstructured":"Garg V, Shen J, Li C, et al. Pharmacokinetic and drug\u2013drug interaction profiles of the combination of tezacaftor\/ivacaftor. Clin Transl Sci. 2019;12:267\u201375.","journal-title":"Clin Transl Sci"},{"key":"1712_CR15","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/j.jcf.2021.04.005","volume":"20","author":"R van der Meer","year":"2021","unstructured":"van der Meer R, Wilms EB, Sturm R, et al. Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls. J Cyst Fibros. 2021;20:e72\u20136.","journal-title":"J Cyst Fibros"},{"key":"1712_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jcf.2022.11.008","volume":"22","author":"R van der Meer","year":"2023","unstructured":"van der Meer R, Wilms EB, Eggermont MN, et al. The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis. J Cyst Fibros. 2023;22:564\u20139.","journal-title":"J Cyst Fibros"},{"key":"1712_CR17","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/ppul.26093","volume":"57","author":"JS Guimbellot","year":"2022","unstructured":"Guimbellot JS, Ryan KJ, Anderson JD, et al. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis. Pediatr Pulmonol. 2022;57:2745\u201353.","journal-title":"Pediatr Pulmonol"},{"key":"1712_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123518","volume":"1213","author":"KJ Ryan","year":"2022","unstructured":"Ryan KJ, Guimbellot JS, Dowell AE, et al. Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1213:123518.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1712_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40262-025-01516-1","volume":"64","author":"P Magnas","year":"2025","unstructured":"Magnas P, Bouazza N, Foissac F, et al. Population pharmacokinetics of elexacaftor, tezacaftor and ivacaftor in a real-world cohort of adults with cystic fibrosis. Clin Pharmacokinet. 2025;64:959\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"1712_CR20","unstructured":"US FDA. Trikafta. Multi-discipline review. AN: 212273Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf. Accessed 18 Mar 2024."},{"key":"1712_CR21","unstructured":"Open-Systems-Pharmacology\/OSPSuite. OSPSuite.Documentation\/PK-Sim Ontogeny Database Version 7.3. https:\/\/github.com\/Open-Systems-Pharmacology\/OSPSuite.Documentation. Accessed 9 Dec 2025."},{"key":"1712_CR22","unstructured":"US FDA. Kaftrio. INN-elexacaftor\/tezacaftor\/ivacaftor. https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/kaftrio-epar-product-information_fr.pdf. Accessed 2 Feb 2026."},{"key":"1712_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/psp4.30","volume":"4","author":"T Shepard","year":"2015","unstructured":"Shepard T, Scott G, Cole S, et al. Physiologically based models in regulatory submissions: output from the ABPI\/MHRA forum on physiologically based modeling and simulation. CPT Pharmacomett Syst Pharmacol. 2015;4:221\u20135.","journal-title":"CPT Pharmacomett Syst Pharmacol"},{"key":"1712_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70245","volume":"18","author":"NH Truong","year":"2025","unstructured":"Truong NH, Benaboud S, Bouazza N, et al. Elexacaftor\/tezacaftor\/ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis. Clin Transl Sci. 2025;18:e70245.","journal-title":"Clin Transl Sci"},{"key":"1712_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060458","volume":"11","author":"R van der Meer","year":"2021","unstructured":"van der Meer R, Wilms EB, Heijerman HGM. CFTR modulators: does one dose fit all? J Pers Med. 2021;11:458.","journal-title":"J Pers Med"},{"key":"1712_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40262-025-01507-2","volume":"64","author":"FA Elzinga","year":"2025","unstructured":"Elzinga FA, Malik PRV, Akkerman OW, et al. Pharmacokinetics of ivacaftor, tezacaftor, elexacaftor, and lumacaftor in special cystic fibrosis populations: a systematic review. Clin Pharmacokinet. 2025;64:999\u20131046.","journal-title":"Clin Pharmacokinet"},{"key":"1712_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jcf.2021.06.005","volume":"20","author":"F Qiu","year":"2021","unstructured":"Qiu F, Habgood MD, Huang Y, et al. Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung. J Cyst Fibros. 2021;20:857\u201364.","journal-title":"J Cyst Fibros"},{"key":"1712_CR28","unstructured":"EMA. Kaftrio. Public assessment report. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kaftrio-epar-public-assessment-report_en.pdf. Accessed 27 Mar 2024."},{"key":"1712_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1156621","volume":"14","author":"H Ibrahim","year":"2023","unstructured":"Ibrahim H, Danish H, Morrissey D, et al. Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series. Front Pharmacol. 2023;14:1156621. https:\/\/doi.org\/10.3389\/fphar.2023.1156621.","journal-title":"Front Pharmacol"},{"key":"1712_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2024.102301","volume":"86","author":"NR Rose","year":"2024","unstructured":"Rose NR, Chalamalla AR, Garcia BA, et al. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024;86:102301.","journal-title":"Pulm Pharmacol Ther"},{"key":"1712_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2024.102314","volume":"86","author":"Z Liu","year":"2024","unstructured":"Liu Z, Anderson JD, Rose NR, et al. Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia. Pulm Pharmacol Ther. 2024;86:102314.","journal-title":"Pulm Pharmacol Ther"},{"issue":"12","key":"1712_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124335","volume":"14","author":"F Lucca","year":"2025","unstructured":"Lucca F, Meneghelli I, Tridello G, et al. Reported adverse events in patients with CF receiving treatment with elexacaftor\/tezacaftor\/ivacaftor: 5 years observational study. J Clin Med. 2025;14(12):4335. https:\/\/doi.org\/10.3390\/jcm14124335.","journal-title":"J Clin Med"},{"key":"1712_CR33","unstructured":"EMA. Alyftrek. INN-deutivacaftor\/tezacaftor\/vanzacaftor. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/alyftrek-epar-public-assessment-report_en.pdf. Accessed 20 Jan 2026."},{"key":"1712_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70225","volume":"15","author":"NH Truong","year":"2026","unstructured":"Truong NH, Benaboud S, Bouazza N, et al. Physiologically based pharmacokinetic modeling of elexacaftor\/tezacaftor\/ivacaftor in infants with cystic fibrosis. CPT Pharmacomet Syst Pharmacol. 2026;15:e70225.","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01712-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01712-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01712-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:21:42Z","timestamp":1791552102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01712-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":34,"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01712-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Philippe Reix declares having received grants and expert fees from Vertex Pharmaceuticals, having been an investigator for Vertex Pharmaceuticals clinical trials, and a past member of the ECFS-clinical trial network executive committee. He has also received grants from the French Patient Organization Vaincre la Mucoviscidose. He is currently the President of the Medical Council. Clotilde Vellat, Laurent Bourguignon, Sabine Cohen, and Romain Garreau have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elexacaftor\u2013tezacaftor\u2013ivacaftor drug monitoring and data collection in our center was part of an ongoing national observational study conducted in children with cystic fibrosis treated by any cystic fibrosis transmembrane conductance regulator modulator in France. This study, called MODUL-CF (NCT04301856), was approved by the Institutional Review Board (IRB IORG0010044, CER AP-HP, H\u00f4pital Necker Enfants Malades, Universit\u00e9 Paris Cit\u00e9, Paris, France).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all parents or legal guardians at inclusion in the MODUL-CF study. Here, we report the results of an ancillary study based on the reuse of data from children followed at our center included in MODUL-CF. In accordance with French regulations, no additional informed consent was required for this ancillary analysis. Children and their parents or legal guardians were informed of the reuse of their data for research purposes and of their right to object to such use.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study participants signed an informed consent regarding the publication of their anonymized data.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All datasets used in this study are appropriately cited in the article (see references).","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model simulation files are accessible upon reasonable request by contacting the corresponding author.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CV, RG, PR, and LB contributed to the study conception and design. Data collection was performed by CV. Data analyses were performed by CV and RG. The first draft of the manuscript was written by CV, and all authors contributed to the manuscript revisions with significant intellectual input.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}